mdBC_logo
 
Username: Password:

A free online accredited CPD program for healthcare professionals

Pharmacotherapy for Type 2 Diabetes Based on the 2018 Diabetes Canada Guidelines

2.00 Mainpro+ Credit(s)

Program available online until: August 20, 2019



This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 2.00 Mainpro+ Credit(s).

Pharmacotherapy for T2D – 2018 Diabetes Canada

/Content/Programs/CaseStudy/KTS_Type2Diabetes_Canada_10285/assets/images/GettyImages-519528622.jpg

In April 2018, Diabetes Canada published new guidelines on the management of diabetes in Canada. The guidelines provide clinicians with some key recommendations based on the most recent evidence. This includes key considerations when considering pharmacotherapy for an individual with type 2 diabetes. 

This program provides some key considerations in common groups of people with type 2 diabetes.  It will review the key considerations when selecting agents to optimize glycemic control and improve outcomes.

Planning Committee

  • Ronald M. Goldenberg, MD, FRCPC, FACE.
  • Harpreet Bajaj, MD, MPH, FACE.
  • Sol Stern, MD, MCFP.
  • Christine Palmay, HBArt Sci., MD, CCFP.
  • John Axler, MD, CCFP, FCFP.

Learning Objectives

Upon successful completion of this continuing education activity, the clinician will be better able to:

  1. Describe the importance of a multifactorial approach to pharmacotherapy in the management of type 2 diabetes, including glycemic control, weight reduction, increasing physical activity, improving dyslipidemia and CV risk reduction
  2. Understand the importance of weight on the management type 2 diabetes and antihyperglycemic selection
  3. Facilitate clinical decision making for selecting the appropriate class of drug for the individual patient
  4. Differentiate between GLP-1 RAs and SGLT2 inhibitors in vascular risk reduction
  5. Review the impact of frailty and renal function on the management of type 2 diabetes

Ask the Expert, Dr. Harpreet Bajaj

  1. What are some of the considerations that you would recommend to all clinicians after diagnosing a person with type 2 diabetes?
  2. What are the key points from the studies regarding SGLT2i’s and GLP-1RA’s and their effects on reducing cardiovascular risk in people with type 2 diabetes?
  3. Which therapies are the safest to use in people with diabetes with reduced renal function and how do you manage the patient’s metformin therapy as their renal function decreases?
  4. How and when would you recommend for GP’s to assess frailty in older people with diabetes?
/Content/Programs/CaseStudy/KTS_Type2Diabetes_Canada_10285/assets/thumbnails/DrBajaj_LP.jpg

mdBriefCase is the practical choice to earn your CPD Credits

Icon of multiple pages

Over 50 accredited courses on mdBriefCase and our sister sites.

The range of courses we offer is unmatched. In addition to our courses we offer accredited newsletters and resource centres. With 22 therapeutic categories, we are sure to expand your medical knowledge.

Icon of a clock

Save Time and Money

Take public transit to work? Like to read in the park? You can access our courses anywhere and earn your CPD credits, all at no cost for you.

Join 30,000+ of your colleagues

Create your free account today